Selective serotonin reuptake inhibitors in the treatment of generalized anxiety disorder

References

• Wittchen HU, Carter RM, Pfisster H. Epidemiology of generalised anxiety disorder in the community and in primary care. Neuropsychiatry (In press).
   Google Scholar
• Carter RM, Wittchen H-U, Pfisster H et al One-year prevalence of subthreshold and threshold DSM-IV generalised anxiety disorder in a nationally representative sample. Depress. Anxien,13,78–88 (2001).
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Carter RM, Pfisster H et al Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. int. PTchopharmacol 15,319–328 (2000).
   PubMed Web of Science ®Google Scholar
• Yonkers 1KA, Dyck IR, Warshaw M et al. Factors predicting the clinical course of generalised anxiety disorder. BE j Psychiatry 176,544–549 (2000).
   Google Scholar
• Beekman AT, Bremmer MA, Deeg DJ et al Anxiety disorders in later life: a report fromthe Longitudinal Aging Study Amsterdam. Int.j Geriatt: Bychiatry 13,717–726 (1998).
   PubMed Web of Science ®Google Scholar
• Weiner E, Bisserbe JC, Maier W et al. Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO study on Psychological Problems in General Healthcare. BE j Psychiatry173\(Suppl. 34), 18–23 (1998).
   Google Scholar
• •• Emphasises that anxiety disorders are common in primary care, but recognized only infrequently.
   Google Scholar
• Kessler RC, DuPont RL, Berglund P et al. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am. J. Psychiatry 156,1915-1923 (1999).
   Google Scholar
• Greenberg PE, Sisitsky T, Kessler RC et al The economic burden of anxiety disorders in the 1990s. J. Clin. fiychiatry60, 427–435 (1999).
   Google Scholar
• Maier W Falkai P. The epidemiology of comorbidity between depression, anxiety disorders and somatic diseases. Int. Clin. PFchopharmacol 14(Suppl. 2), 51–56 (1999).
   Google Scholar
• Connor KM, Davidson JRT. Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. Biol. PFchiatry 44, 1286–1294 (1998).
   PubMed Web of Science ®Google Scholar
• Chamey DS, Woods SW, Heninger GR. Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Res. 27,173–182 (1989).
   PubMed Web of Science ®Google Scholar
• Sevy S, Papadimitriou GN, Surmont DW et al Noradrenergic function in generalized anxiety disorder, major depressive disorder and healthy subjects. Biol. Psychiatry 25, 141–152 (1989).
   PubMed Web of Science ®Google Scholar
• Weizman R, Tanne Z, Granek M et al Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients. Eur Pharmacol 138,289–292 (1987).
   PubMed Web of Science ®Google Scholar
• Rocca P, Ferrero P, Gualerzi A et al Peripheral-type benzodiazepine receptors in anxiety disorders. Acta PFchiatr Scaml 84, 537–544 (1991).
   PubMed Web of Science ®Google Scholar
• Rosenberg C, Damsbo N, Fuglum E et al 1994. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. Int. Gun. Psychopharmacol 9\(Suppl. 1), 41–48 (1994).
   Google Scholar
• Jefferson J, Greist J. A double-blind comparison of citalopram and paroxetine in the treatment of patients with depression and anxiety. Presented at American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 10–14, 2000.
   Google Scholar
• Stahl S. Placebo-controlled comparison of the selective serotonin re-uptake inhibitors citalopram and sertraline. Bid Psychiatry 48,894–901 (2000).
   PubMed Web of Science ®Google Scholar
• Hyttel J, Bsego IQ, Perregard JA, Sanchez C. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. j Neural 7iansm. Gen. Sect. 88, 157–160 (1992).
   Google Scholar
• Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums 7\(Suppl. 1), S40—S44 (2002).
   Google Scholar
• Davidson J, Bose A, Su G. Escitalopram in the treatment of generalized anxiety disorder. Int. .1. Neuropsychopharmacol 5\(Suppl. 1), S214 (2002).
   Google Scholar
• Fairbanks JM, Pine DS, Tancer NK et al Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. J. Child Adolesc fiychopharmacol7 (1), 17–29 (1997).
   PubMed Web of Science ®Google Scholar
• Hurst M, Lamb HM. Fluoxetine: a review of its use in anxiety disorders and mixed anxiety and depression. CNS Drug 14,51–80 (2000).
   Web of Science ®Google Scholar
• Sonawalla SB, Spillmann MK, Kolsky AR et al Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. J. Gun. Psychiatry60(9), 580–583 (1999).
   Google Scholar
• Baldwin DS. SSRIs in the treatment of generalised anxiety disorder. In:SSRh in Depression andAnxiev Montgomery SA, den Boer JA (Eds). Wiley, Chichester, UK, 193–209 (2001).
   Google Scholar
• •Review of evidence supporting use of SSRI in GAD treatment.
   Google Scholar
• Rocca P, Fonzo V, Scotta M et al Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scaml 95, 444–450 (1997).
   PubMed Web of Science ®Google Scholar
• Pollack MET, Zaninelli R, Goddard A et al Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. j Clin. Psychiatry62, 350–357 (2001).
   PubMed Web of Science ®Google Scholar
• ••Key study showing that SSRI treatmentcan be effective in GAD.
   Google Scholar
• Stocchi G, Nordera G, Jokinen RII et al Continued benefit of long-term paroxetine treatment for generalised anxiety disorder. Int. .1. Neuropsychopharmacol 5 (Suppl. 1), S213 (2002).
   Google Scholar
• Allgulander C, Cloninger CR, Przybeck TR, Brandt L. Changes on the temperament and character inventory after paroxetine treatment in volunteers with generalized anxiety disorder. PFchopharmacol Bull 34(2), 165–166 (1998).
   PubMedGoogle Scholar
• Baldwin DS, McCafferty J, Bellew K et al Improving the disability and impairment associated with generalised anxiety disorder with paroxetine treatment. int. J. Neuropsychopharmacol 5 (Suppl. 1), S213 (2002).
   Google Scholar
• Fontaine R, Ontiveros A, Elie R et al. Double- blind comparison of nefazodone, imipramine and placebo in major depression. j Gun. Psychiatry55, 234–241 (1994).
   Google Scholar
• Hedges DW, Reimherr FW, Strong RE et al An open trial of nefazodone in adult patients with generalised anxiety disorder. PFchopharmacol Bull 32,671–676 (1996).
   PubMedGoogle Scholar
• Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed out-patients. J. Affect. Disord. 47, 55–62 (1998).
   Google Scholar
• Davidson JR, DuPont RL, Hedges D et al Efficacy, safety and tolerability of venlafaxine extended release and buspirone in out-patients with generalised anxiety disorder. J. Gun. Psychiatry 60,528–530 (1999).
   Google Scholar
• Rickels K, Pollack M, Sheehan D et al Efficacy of venlafaxine extended-release (XR) capsules in nondepressed out-patients with generalised anxiety disorder. Am. J. Psychiatry 157,968–974 (2000).
   PubMed Web of Science ®Google Scholar
• Salinas E. Placebo-controlled evidence for the use of antidepressants in generalised anxiety disorder. Eur. Neuropsychopharmacol 9\(Suppl. 5), S176 (1999).
   Google Scholar
• Hackett D, Meoni P, White C et al. Efficacy of short and long-term venlafaxine ER treatment for somatic and psychic symptoms of GAD. Eur. Neuropsychopharmacol 10\(Suppl. 10), S337 (2000).
   Google Scholar
• Gelenberg AJ, Lydiard RB, Rudolph RL et al Efficacy of venlafaxine extended-release capsules in nondepressed out-patients with generalised anxiety disorder. JÁ MA 283,3082–3088 (2000).
   PubMed Web of Science ®Google Scholar
• Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br. J. fiychiatry179,15–22 (2001).
   Google Scholar
• Sitsen JMA, Moors J. Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms: results from a placebo-controlled trial. Drug- Invest. 8,339–344 (1994).
   Google Scholar
• Fawcett J, Barkin RL. Meta-analysis of eight randomised, double-blind, controlled trials of mirtazapine, a novel antidepressant drug.j Clin. Psychiatry 59,123–127 (1998).
   PubMed Web of Science ®Google Scholar
• Goa KL, Ward A. Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 32,114–129 (1986).
   PubMed Web of Science ®Google Scholar
• Goldberg HL, Finnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am. J. fiychiatry 136,1184–1187 (1979).
   PubMed Web of Science ®Google Scholar
• Gammans RE, Stringfellow JC, Hvidzos AJ et al Use of buspirone in patients with generalised anxiety disorder and coexisting depressive symptoms: a meta-analysis of eight randomised controlled trials. Neuropsychobiol 25,193–201 (1992).
   PubMed Web of Science ®Google Scholar
• Sramek JJ, Tansman M, Sun i etal. Efficacy of buspirone in generalised anxiety disorder with coexisting mild depressive symptoms. J. Clin. Psychiatry 57,287–291 (1996).
   Google Scholar
• Ansseau M, Papart P, Gerard MAA et al Controlled comparison of buspirone and oxazepam in generalised anxiety. Neuropsychobiol 24,74–78 (1990).
   PubMed Web of Science ®Google Scholar
• Rickets K, Schweizer E. The spectrum of generalised anxiety in clinical practice: the role of short-term, intermittent treatment. Br. Psychiatry173\(Suppl. 34), 49–54 (1998).
   Google Scholar
• Bradford LD, Stevens G. Double-blind, placebo-controlled fixed dose study of flesinoxan in generalized anxiety disorder. Am. Coll Neumpsychopharmacol 167.
   Google Scholar
• Gould RA, Otto MW, Pollack MH et al Cognitive behavioural and pharmacological treatment of generalised anxiety disorder: a preliminary meta-analysis. Behar/. Ther. 28, 285–305 (1997).
   Web of Science ®Google Scholar
• Lader MET. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol 9(Suppl. 9), S399—S405 (1999).
   Google Scholar
• •• Highlights the potential drawbacks of benzodiazepine treatment of anxiety
   Google Scholar
• Argyropoulos SV, Nutt DJ. The use of benzodiazepines in anxiety and other disorders. Eur Neuropsychophatmacol 9\(Suppl. 9), S407—S412 (1999).
   Google Scholar
• ••Argues that benzodiazepines should not bewithheld from chronically ill, substantially disabled patients.
   Google Scholar
• Aufdembrinke B. Abercarnil, a new beta- carboline, in the treatment of anxiety disorders. Br. PTchiatry173,55–63 (1998).
   Google Scholar
• Ballenger JC, McDonald S, Noyes R et al The first double-blind placebo-controlled trial of a partial BZD agonists abercamil (ZK-112-119) in generalised anxiety disorder. fiychophatmacol Bull. 27,171–179 (1991).
   PubMed Web of Science ®Google Scholar
• Lydiard RB, Ballenger JC, Rickels K. A double-blind evaluation of the safety and efficacy of abercarnil, alprazolam and placebo in out-patients with generalised anxiety disorder. J. Clin. Psychiatry 58\(Suppl. 11), 11–18 (1997).
   Google Scholar
• Pollack MH, Worthington JH, Manfro GG et al. Abercarnil for the treatment of generalised anxiety disorder: a placebo-controlled comparison of two dose ranges of abercarnil and buspirone. j Clin. fiychMtry58\(Suppl. 11), 19–23 (1997).
   Google Scholar
• Small GW, Bystritsky A. Double-blind, placebo-controlled trial of two doses of abercarnil for geriatric anxiety. j Clin. fiychMtry58\(Suppl. 11), 24–29 (1997).
   Google Scholar
• Adams JB, Pyke RE, Costa J et al. A double-blind, placebo-controlled study of a CCK-B antagonist, CIO-988, in patients with generalised anxiety disorder. J. Clin. fiychophatmacol 15,428–434 (1995).
   Google Scholar
• Field MJ, Oles RJ, Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. BE J. Pharmacol 132,1–4 (2001).
   Google Scholar
• •Description of the preclinical and pharmacological properties of a promising compound for the treatment of GAD.
   Google Scholar
• Pande AC, Crockatt JG, Janney C etal. Pregabalin, a novel agent, in the treatment of generalized anxiety disorder. Presented at American Psychiatric Association, San Diego, USA, May 2000.
   Google Scholar
• Rickets K, Pollack MET, Lydiard RB et al Comparison of the efficacy and safety of pregabalin and alprazolam in generalised anxiety disorder. Int. J. NeuropTchophalmacol 5 (Suppl. 1), S213 (2002).
   Google Scholar
• Gould RA, Otto MW, Pollack MH, Yap L. Cognitive behavioural and pharmacological treatment of generalised anxiety disorder: a preliminary meta-analysis. Behar/. Ther. 28, 285–305 (1997).
   Web of Science ®Google Scholar
• Durham RC, Fisher PL, Trevling LR et al One year follow-up of cognitive therapy, analytic psychotherapy and anxiety management training for generalised anxiety disorder: symptom change, medication usage and attitudes to treatment. Behav. Consult. fiychother. 27, 19–35 (1999).
   Google Scholar
• Lader MH, Bond AJ. Interaction of pharmacological and psychological treatments of anxiety. BE J. fiychiatry 173\(Suppl. 34), 42–48 (1998).
   Google Scholar
• Durham RC, Turvey AA. Cognitive therapy versusbehaviour therapy in the treatment of chronic generalised anxiety. fkhav. Res. Ther. 25,229–234 (1987).
   PubMed Web of Science ®Google Scholar
• Wardle J. Behaviour therapy and benzodiazepines: allies or antagonists? BE J. Psychiatry 156,163–168 (1990).
   Google Scholar
• Power KG, Simpson RJ, Swanson V et al A controlled comparison of cognitive-behaviour therapy, diazepam and placebo, alone and in combination, for the treatment of generalised anxiety disorder. J. Anx. Dis. 4,267–292 (1990).
   Web of Science ®Google Scholar
• Keller MB, McCullough JP, Klein DN et al. A comparison of nefazodone, the cognitive-behavioural analysis system of psychotherapy and their combination for the treatment of chronic depression. N Engl. Med. 342,1462–1470 (2000).
   PubMed Web of Science ®Google Scholar
• Barlow DH, Gorman JM, Shear MK, Woods SW Cognitive-behavioural therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JA/V/A 283,2529–2536 (2000).
   Google Scholar
• ECNP Consensus meeting, March 2000. Guidelines for investigating efficacy in GAD. Eur Neuropsychophalmacol 12,81-87 (2002).
   Google Scholar
• ••The most recent guidelines for evaluatingefficacy in GAD treatment.
   Google Scholar